Aeroneb Pro

Aerogen is an emerging specialty company dedicated to improving patients' lives by providing innovative inhaled drug products to advance the treatment of respiratory disorders and chronic diseases. The company is focused on efficient, convenient delivery of aerosolised drugs to the lungs, and through the lungs to the bloodstream.

Aerogen's range of current and future products includes specialised nebulisers and breath-activated inhalers for marketing by Aerogen, as well as novel inhalers for leading pharmaceutical and biotechnology companies.

Aerogen's penny-sized aerosol generator sets a new performance standard for the aerosolisation of drugs. Without using propellants, Aerogen's aerosol generator can produce aerosols tailored for respiratory or systemic therapy, and efficiently delivers small molecules, peptides and proteins, in solution or suspension. When the aerosol generator is incorporated into Aerogen's proprietary nebuliser or inhaler platforms, the opportunities for creating improved therapies for patients around the globe are almost limitless.

Aerogen introduced its first commercial product, the Aeroneb® Portable Nebuliser System, in June 2001 to benefit the four million respiratory patients in the U.S. who require frequent nebuliser therapy for the treatment of asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF).

Aerogen's second commercial nebuliser product, the Aeroneb® Professional Nebuliser System, is designed to improve the administration of respiratory therapy in hospitals to patients on ventilators, in emergency rooms or on hospital floors. Both nebuliser products are designed to deliver commercially available medications that have been cleared for use with general-purpose nebulisers.

AeroGen, Inc. is headquartered in Sunnyvale, California. Ehud Ivri founded the company (as Fluid Propulsion Technologies) in 1991 with a novel method for controlled fluid aerosolisation. In April 1997, the company name was changed to Aerogen, Inc.